$KALV +114% on public offering

$KALV is a pharmaceuticals company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company’s product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors.

Here is the link of the press release.

Here is the graph of the day.

Here is the 30 day overview.